MedTrace Logo

Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient

NCT02090127 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2015-07-29

No results posted yet for this study

Summary

Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient

Conditions

  • Mullerian Mixed Tumor of Ovary

Interventions

DRUG

ficlatuzumab

humanized anti-hepatocyte growth factor (HGF) monoclonal antibody IV administration at 16.5mg/kg every 2 weeks with a ±2 day window around dosing dates, as long as subject is deriving clinical benefit as determined by the Investigator

Sponsors & Collaborators

  • AVEO Pharmaceuticals, Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02090127 on ClinicalTrials.gov